| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| Cost of Revenue | $0 | — | — |
| R&D Expense | $74K | -7.3% | -13.8% |
| Operating Income | -$226K | +7.1% | +11.8% |
| Interest Expense | $10K | +0.0% | -2.3% |
| Income Tax | $0 | — | — |
| Net Income | -$246K | +6.5% | +10.7% |
| EPS (Diluted) | $0.00 | — | +100.0% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2K | -38.2% | -53.3% |
| Current Assets | $2K | -58.2% | -53.3% |
| Total Assets | $102K | -2.6% | -2.1% |
| Current Liabilities | $17.4M | +1.4% | +6.5% |
| Total Liabilities | $17.4M | +1.4% | +6.5% |
| Stockholders' Equity | -$17.3M |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$261K | — | — |
| Financing Cash Flow | $260K | — | — |
| -6.5% |